vs

Side-by-side financial comparison of Tarsus Pharmaceuticals, Inc. (TARS) and T1 Energy Inc. (TE). Click either name above to swap in a different company.

T1 Energy Inc. is the larger business by last-quarter revenue ($210.5M vs $151.7M, roughly 1.4× Tarsus Pharmaceuticals, Inc.). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -62.0%, a 56.5% gap on every dollar of revenue. T1 Energy Inc. produced more free cash flow last quarter ($55.0M vs $13.0M).

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

Sony Energy Devices Corporation , is a Japanese multinational company specializing in a variety of areas in the energy industry, and is a wholly owned subsidiary and part of the Devices Group of Sony. The company was established in February 1975 in Fukushima, Japan.

TARS vs TE — Head-to-Head

Bigger by revenue
TE
TE
1.4× larger
TE
$210.5M
$151.7M
TARS
Higher net margin
TARS
TARS
56.5% more per $
TARS
-5.5%
-62.0%
TE
More free cash flow
TE
TE
$42.0M more FCF
TE
$55.0M
$13.0M
TARS

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
TARS
TARS
TE
TE
Revenue
$151.7M
$210.5M
Net Profit
$-8.4M
$-130.6M
Gross Margin
10.0%
Operating Margin
-5.3%
-45.0%
Net Margin
-5.5%
-62.0%
Revenue YoY
128.4%
Net Profit YoY
63.8%
-375.2%
EPS (diluted)
$-0.17
$-0.87

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TARS
TARS
TE
TE
Q4 25
$151.7M
Q3 25
$118.7M
$210.5M
Q2 25
$102.7M
$132.8M
Q1 25
$78.3M
$53.5M
Q4 24
$66.4M
Q3 24
$48.1M
$0
Q2 24
$40.8M
$0
Q1 24
$27.6M
$0
Net Profit
TARS
TARS
TE
TE
Q4 25
$-8.4M
Q3 25
$-12.6M
$-130.6M
Q2 25
$-20.3M
$-31.9M
Q1 25
$-25.1M
$-16.2M
Q4 24
$-23.1M
Q3 24
$-23.4M
$-27.5M
Q2 24
$-33.3M
$-27.0M
Q1 24
$-35.7M
$-28.5M
Gross Margin
TARS
TARS
TE
TE
Q4 25
Q3 25
10.0%
Q2 25
24.7%
Q1 25
33.3%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
TARS
TARS
TE
TE
Q4 25
-5.3%
Q3 25
-12.2%
-45.0%
Q2 25
-21.6%
-22.0%
Q1 25
-33.5%
-44.2%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Q1 24
-136.5%
Net Margin
TARS
TARS
TE
TE
Q4 25
-5.5%
Q3 25
-10.6%
-62.0%
Q2 25
-19.8%
-24.0%
Q1 25
-32.1%
-30.4%
Q4 24
-34.8%
Q3 24
-48.7%
Q2 24
-81.6%
Q1 24
-129.4%
EPS (diluted)
TARS
TARS
TE
TE
Q4 25
$-0.17
Q3 25
$-0.30
$-0.87
Q2 25
$-0.48
$-0.21
Q1 25
$-0.64
$-0.11
Q4 24
$-0.57
Q3 24
$-0.61
$-0.20
Q2 24
$-0.88
$-0.19
Q1 24
$-1.01
$-0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TARS
TARS
TE
TE
Cash + ST InvestmentsLiquidity on hand
$417.3M
$34.1M
Total DebtLower is stronger
$72.4M
$547.3M
Stockholders' EquityBook value
$343.4M
$96.9M
Total Assets
$562.2M
$1.4B
Debt / EquityLower = less leverage
0.21×
5.65×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TARS
TARS
TE
TE
Q4 25
$417.3M
Q3 25
$401.8M
$34.1M
Q2 25
$381.1M
$8.5M
Q1 25
$407.9M
$48.9M
Q4 24
$291.4M
Q3 24
$317.0M
$181.9M
Q2 24
$323.6M
$219.6M
Q1 24
$298.5M
$249.9M
Total Debt
TARS
TARS
TE
TE
Q4 25
$72.4M
Q3 25
$72.3M
$547.3M
Q2 25
$72.1M
$591.2M
Q1 25
$72.0M
$603.2M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
$602.3M
Stockholders' Equity
TARS
TARS
TE
TE
Q4 25
$343.4M
Q3 25
$335.1M
$96.9M
Q2 25
$332.6M
$183.9M
Q1 25
$342.5M
$201.9M
Q4 24
$224.5M
Q3 24
$237.5M
$538.7M
Q2 24
$252.2M
$561.6M
Q1 24
$275.2M
$582.3M
Total Assets
TARS
TARS
TE
TE
Q4 25
$562.2M
Q3 25
$534.6M
$1.4B
Q2 25
$495.0M
$1.4B
Q1 25
$500.8M
$1.4B
Q4 24
$377.0M
Q3 24
$376.3M
$615.0M
Q2 24
$376.8M
$644.4M
Q1 24
$349.3M
$670.3M
Debt / Equity
TARS
TARS
TE
TE
Q4 25
0.21×
Q3 25
0.22×
5.65×
Q2 25
0.22×
3.21×
Q1 25
0.21×
2.99×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×
1.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TARS
TARS
TE
TE
Operating Cash FlowLast quarter
$19.3M
$63.9M
Free Cash FlowOCF − Capex
$13.0M
$55.0M
FCF MarginFCF / Revenue
8.6%
26.1%
Capex IntensityCapex / Revenue
4.2%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M
$-42.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TARS
TARS
TE
TE
Q4 25
$19.3M
Q3 25
$18.3M
$63.9M
Q2 25
$-29.4M
$33.4M
Q1 25
$-20.7M
$-44.8M
Q4 24
$-22.2M
Q3 24
$-8.7M
$-28.4M
Q2 24
$-14.4M
$-28.0M
Q1 24
$-37.8M
$-16.2M
Free Cash Flow
TARS
TARS
TE
TE
Q4 25
$13.0M
Q3 25
$16.3M
$55.0M
Q2 25
$-30.4M
$10.6M
Q1 25
$-21.2M
$-74.0M
Q4 24
$-22.3M
Q3 24
$-8.9M
$-34.0M
Q2 24
$-15.4M
$-35.6M
Q1 24
$-38.0M
$-37.7M
FCF Margin
TARS
TARS
TE
TE
Q4 25
8.6%
Q3 25
13.8%
26.1%
Q2 25
-29.6%
8.0%
Q1 25
-27.1%
-138.4%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
TARS
TARS
TE
TE
Q4 25
4.2%
Q3 25
1.6%
4.2%
Q2 25
1.0%
17.2%
Q1 25
0.8%
54.5%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Q1 24
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TARS
TARS

Segment breakdown not available.

TE
TE

Related Party$120.1M57%
Nonrelated Party$90.4M43%

Related Comparisons